BFM
CRNX icon

Boothbay Fund Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Boothbay Fund Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-30,418
Closed -$1.35M – 2035
2025
Q3 		$1.27M Sell
30,418
-78,551
-72% -$2.51M 0.02% 738
2025
Q2 		$3.13M Sell
108,969
-31,004
-22% -$957K 0.06% 402
2025
Q1 		$4.69M Buy
139,973
+2,221
+2% +$82.9K 0.12% 228
2024
Q4 		$7.04M Buy
137,752
+28,327
+26% +$1.58M 0.17% 169
2024
Q3 		$5.59M Sell
109,425
-41,499
-27% -$2.14M 0.13% 220
2024
Q2 		$6.76M Sell
150,924
-11,602
-7% -$536K 0.16% 145
2024
Q1 		$7.61M Buy
162,526
+17,615
+12% +$689K 0.15% 116
2023
Q4 		$5.16M Sell
144,911
-22,327
-13% -$685K 0.13% 187
2023
Q3 		$4.97M Buy
167,238
+70,433
+73% +$1.45M 0.12% 217
2023
Q2 		$1.74M Buy
+96,805
New +$1.93M 0.04% 614
2020
Q3 		– Sell
-11,855
Closed -$208K – 1069
2020
Q2 		$208K Buy
+11,855
New +$202K 0.01% 790

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Boothbay Fund Management's CRNX Position: Q4 2025 in Review

Boothbay Fund Management sold out of Crinetics Pharmaceuticals (CRNX) in Q4 2025, closing a stake of 30,418 shares — an estimated $1.35M sold.

Boothbay Fund Management first reported a position in CRNX in Q2 2020 and held it in 11 quarters. The position peaked at $7.61M in Q1 2024. 240 funds tracked by Wall St. Rank hold CRNX as of Q4 2025.

  • Boothbay Fund Management reported no remaining Crinetics Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Boothbay Fund Management sold 30,418 Crinetics Pharmaceuticals shares in Q4 2025, an estimated $1.35M.
  • Boothbay Fund Management first reported a position in Crinetics Pharmaceuticals in Q2 2020 and held it in 11 quarters.
  • Boothbay Fund Management's Crinetics Pharmaceuticals position peaked at $7.61M in Q1 2024.
  • 240 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q4 2025.

Based on Boothbay Fund Management's 13F filing for Q4 2025, filed 17 Feb 2026.